HCL
HOSPICES CIVILS DE LYON

PRESS RELEASE

LYON, France 9 February 2023

Hospices Civils de Lyon announces the treatment of a non-small cell lung cancer patient with Clonal Neoantigen Reactive T Cells (cNeT) for the first time in France

Hospices Civils de Lyon today announced that a patient recently underwent an infusion of clonal neoantigen reactive T cells (cNeT) for the treatment of non-small lung cancer (NSCLC). This achievement at Lyon University Hospital marks the first cNeT treatment of an NSCLC patient in France due to the tight collaboration of the Hospital's pulmonology and thoracic oncology department, surgery department, hematology department, Intensive Care Unit, and the pharmacy team. This milestone was reached within the CHIRON clinical trial of adoptive cancer therapy conducted by Achilles Therapeutics plc (London, United Kingdom). Hospices Civils de Lyon is currently the only site in France for this trial.

"This is a very encouraging step for the fight against lung cancer," said Prof. Sébastien Couraud, the Principal Investigator of the CHIRON trial at Lyon. "We were able to reach this milestone because we collaborated together, with competencies from different teams. This is a great example of what can be achieved in clinical research in university hospitals."

According to the US National Cancer Institute (NCI), adoptive therapy is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. In cancer therapy, T cells are usually taken from the patient's own blood or tumor tissue, grown in large numbers in the laboratory, and then given back to the patient to help the immune system fight the cancer. Sometimes, the T cells are changed in the laboratory to make them better able to target the patient's cancer cells and kill them. Types of adoptive cell therapy include chimeric antigen receptor T-cell (CAR T-cell) therapy and tumor-infiltrating lymphocyte (TIL) therapy.

CAR-T are used in hematologic cancers and notably in Lyon University Hospital which hosts the largest center for CAR-T treatments in Europe, with more than 300 patients treated. TILs were previously investigated in various cancers, mainly melanoma.

➔ About Hospices Civils de Lyon

For over 200 years, Hospices Civils de Lyon has been serving the inhabitants of Lyon with its medical expertise. The public service values driving its staff are a guarantee that all patients will be welcomed unconditionally and, as such, benefit from the best care and innovations that this major university hospital centre has to offer. Also involved in the city's economic, social and urban development, Hospices Civils de Lyon has a history inextricably linked to that of the city and contributes to its development. Hospices Civils de Lyon is particularly at the heart of the healthcare ecosystem of Greater Lyon, one of the major biotechnology and

CONTACT : presse@chu-lyon.fr
Laure BELLEGOU – 04 72 40 74 48

healthcare markets in Europe. Hospices Civils de Lyon is France's second university hospital centre (CHU). HCL includes a staff of 24,000 of which 5000 are physicians and over 11,000 are nursing staff. It federates 13 facilities, including three predominantly general facilities providing emergency, medical and surgical services in a wide range of disciplines, seven specialist facilities and four geriatric facilities.

➔ **About Achilles Therapeutics**

Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.